OverviewSuggest Edit

Biocon is a global biopharmaceutical company. It manufactures biologics, biosimilar insulins, and antibodies. The company focuses on the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides.

TypePublic
Founded1978
HQBengaluru, IN
Websitebiocon.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Mar 2021)13,500(+8%)
Revenue (FY, 2021)₹73.6 B(+13%)
Share Price (Nov 2021)₹347.9
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Biocon

Siddharth Mittal

Siddharth Mittal

CEO and Managing Director
Kiran Mazumdar Shaw

Kiran Mazumdar Shaw

Executive Chairperson
Arun Chandavarkar

Arun Chandavarkar

Managing Director, Biocon Biologics
Jonathan Hunt

Jonathan Hunt

CEO & Managing Director, Syngene International
Shreehas P Tambe

Shreehas P Tambe

Deputy Chief Executive Officer, Biocon Biologics
M. Damodaran

M. Damodaran

Independent and Non-Executive Director
Show more

Biocon Office Locations

Biocon has offices in Bengaluru, Cambridge, Dublin, Kuala Lumpur and in 5 other locations
Bengaluru, IN (HQ)
20th KM, Hosur Road, Electronic City
Bengaluru, IN
Biocon House, Semicon Park, Electronics City, Phase – II, Hosur Road
Dublin, IE
9 Clare St
Kuala Lumpur, MY
Level 7, Menara Milenium Jalan Damanlela, Pusat Bandar Damansara, Damansara Heights
Puchong, MY
Unit D-3-5, Level 5, Block D Setiawalk, Persiaran Wawasan Pusat Bandar
Delémont, CH
Rue de l'Avenir 2
Show all (10)

Biocon Financials and Metrics

Biocon Revenue

Embed Graph
View revenue for all periods
Biocon's revenue was reported to be ₹73.6 b in FY, 2021 which is a 12.7% increase from the previous period.
INR

Revenue (Q1, 2022)

18.1b

Gross profit (Q1, 2022)

12.0b

Gross profit margin (Q1, 2022), %

66.1%

Net income (Q1, 2022)

1.1b

Market capitalization (10-Nov-2021)

414.3b

Closing stock price (10-Nov-2021)

347.9
Biocon's current market capitalization is ₹414.3 b.
Annual
INRFY, 2019FY, 2020FY, 2021

Revenue

56.6b65.3b73.6b

Revenue growth, %

15%13%

Cost of goods sold

19.0b20.5b22.1b

Gross profit

37.6b44.8b51.5b
Quarterly
INRQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

14.9b16.1b17.8b16.9b17.6b18.8b18.1b

Cost of goods sold

4.2b4.8b5.8b5.4b5.3b5.6b6.1b

Gross profit

10.7b11.3b12.1b11.5b12.3b13.2b12.0b

Gross profit Margin, %

72%70%68%68%70%70%66%
INRFY, 2019

Revenue/Employee

6.4m
Show all financial metrics

Biocon Acquisitions / Subsidiaries

Company NameDateDeal Size
AxiCorp GmbHFebruary 11, 2008
Bicara Therapeutics Inc
Biocon Academy
Biocon Biologics do Brasil Ltda.
Biocon Biologics FZ–LLC
Biocon Biologics Healthcare Malaysia SDN. BHD
Biocon Biologics Inc.
Biocon Biologics Limited
Biocon Biologics UK Limited
Biocon Biosphere Limited
Show more

Biocon Revenue Breakdown

Embed Graph

Biocon revenue breakdown by business segment: 28.8% from Research Services, 30.8% from Generics, 37.0% from Biosimilars and 3.4% from Other

Show all human capital metrics

Biocon Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Biocon Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Biocon Online and Social Media Presence

Embed Graph

Biocon News and Updates

Biocon - Biosimilar Traction Buoys Up Q3, Momentum To Be Key: ICICI Direct

Biocon - Biosimilar Traction Buoys Up Q3, Momentum To Be Key: ICICI Direct

Biocon - Steady Q2; Generics Business Remains Under Pressure: ICICI Securities

Biocon - Steady Q2; Generics Business Remains Under Pressure: ICICI Securities

Biocon Q2 Review - Steady Numbers Amid Better Margins: ICICI Direct

Biocon Q2 Review - Steady Numbers Amid Better Margins: ICICI Direct

Global HER2 Inhibitors Market Report 2021-2025 & 2030 Featuring F. Hoffmann-La Roche., Merck, Novartis, Pfizer, Puma Biotechnology, Boehringer-Ingelheim, Mylan, and Biocon

Dublin, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The "HER2 Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global HER2 inhibitors market is expected to grow from $5.98 billion in 2020 to $6.4 billion in 2021 at a co…

Biocon Unit To Offer 15% Stake To Serum Institute’s Arm In A Strategic Alliance

Adar Poonawalla will have a board seat in Biocon Biologics.

Insights on the Automated Insulin Delivery System Global Market to 2026 - Featuring Biocon, Dexcom and Digital Medics Among Others

Dublin, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The "Automated Insulin Delivery System Market Research Report by Disease Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering. The Global Automated Insulin Delivery System Ma…
Show more

Biocon Blogs

Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr

The post Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr appeared first on Biocon.

The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart

The post The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart appeared first on Biocon.

Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents

The post Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents appeared first on Biocon.

Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval

The post Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval appeared first on Biocon.

Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East

The post Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East appeared first on Biocon.

Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index

The post Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index appeared first on Biocon.
Show more

Biocon Frequently Asked Questions

  • When was Biocon founded?

    Biocon was founded in 1978.

  • Who are Biocon key executives?

    Biocon's key executives are Siddharth Mittal, Kiran Mazumdar Shaw and Arun Chandavarkar.

  • How many employees does Biocon have?

    Biocon has 13,500 employees.

  • What is Biocon revenue?

    Latest Biocon annual revenue is ₹73.6 b.

  • What is Biocon revenue per employee?

    Latest Biocon revenue per employee is ₹5.5 m.

  • Who are Biocon competitors?

    Competitors of Biocon include Cipla, Sun Pharma and Idorsia.

  • Where is Biocon headquarters?

    Biocon headquarters is located at 20th KM, Hosur Road, Electronic City, Bengaluru.

  • Where are Biocon offices?

    Biocon has offices in Bengaluru, Cambridge, Dublin, Kuala Lumpur and in 5 other locations.

  • How many offices does Biocon have?

    Biocon has 10 offices.